Bristol-Myers immunotherapy combination extends survival in melanoma – WHTC
Sports Perspectives |
Bristol-Myers immunotherapy combination extends survival in melanoma
WHTC (Reuters) – Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64 percent on the combination therapy still alive after two years … BMS to Use Foundation Medicine Platform in Immuno-Oncology Partnership |
